Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1984; 4:105-110
© 1984 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shenasa, M
Right arrow Articles by Akhtar, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shenasa, M
Right arrow Articles by Akhtar, M

Effect of amiodarone on conduction and refractoriness of the His-Purkinje system in the human heart

M Shenasa, S Denker, R Mahmud, M Lehmann, A Estrada, and M Akhtar

Although the antiarrhythmic aspect of amiodarone has been extensively studied, its effects on His-Purkinje system conduction and refractoriness have not been systematically investigated in human beings. In 24 patients, anterograde His-Purkinje system conduction (HV intervals) and variables of His-Purkinje system refractoriness using the ventricular extrastimulus (V2) technique were analyzed before and after long-term therapy with amiodarone. The mean duration of amiodarone therapy at the time of repeat study was 16.2 +/- 7.7 weeks (range 11 to 42). The anterograde His-Purkinje system conduction time (HV interval) measured 49.6 +/- 9.5 ms (range 40 to 80) before and 60.6 +/- 10.7 ms (range 45 to 90) after amiodarone (p less than 0.005). During retrograde refractory period studies, the longest V1V2 interval at which a retrograde His bundle potential (H2) emerged from the V2 electrogram (relative refractory period of the His-Purkinje system) was consistently longer after amiodarone as compared with the control period (376.4 +/- 46.6 versus 318.8 +/- 33.1 ms, p less than 0.005). Similarly, the shortest and longest His-Purkinje system conduction times ( V2H2 interval) at comparable V1V2 intervals were uniformly and significantly prolonged after administration of the drug. Amiodarone also abolished macroreentry in the His-Purkinje system in six of the nine patients who showed such reentry during the control period. The effective refractory period of the ventricular myocardium was also increased from a mean of 227.1 +/- 13.9 to 259.2 +/- 20.2 ms (p less than 0.005) in this series of patients.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
I. Kodama, K. Kamiya, and J. Toyama
Cellular electropharmacology of amiodarone
Cardiovasc Res, July 1, 1997; 35(1): 13 - 29.
[Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
K. Nademanee, H. E. Noll, and G. K. Feld
Effects of Sotalol on His-Purkinje Conduction and Refractoriness in Humans
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 9 - 16.
[Abstract] [PDF]


Home page
CirculationHome page
J. N. Nanas and J. W. Mason
Pharmacokinetics and Regional Electrophysiological Effects of Intracoronary Amiodarone Administration
Circulation, January 15, 1995; 91(2): 451 - 461.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement